The analysis of ankylosing spondylitis patients receiving biological therapies: data from TURKBIO registry

Güllüoğlu, Hacer

doi:10.2399/raed.14.46220

Cited by 1 publication

(1 citation statement)

References 29 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gender, age, time elapsed after diagnosis (disease duration), comorbidities, and smoking habits of the patients were recorded. The prepandemic planned treatments of the patients were evaluated through their last visit registered in the TURKBIO database [5]. During the study period interviews, the drugs currently used by the patients [NSAID (nonsteroidal anti-inflammatory drug), glucocorticoid (GC), conventional DMARD, conventional synthetic DMARD) and b/ts DMARD] and their doses were recorded.…”

Section: Patientsmentioning

confidence: 99%

How has the COVID-19 pandemic affected our rheumatology patients using biological/targeted DMARDs?

Gülle¹,

Erez²,

Karakas³

et al. 2023

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: We aimed to investigate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the course and treatment of patients with inflammatory rheumatic musculoskeletal disease (iRMD) using biologic or targeted synthetic disease modifying and rheumatic drugs (b/tsDMARDs). Methodology: The study was carried out in two stages: in the first stage we investigated the delay of b/tsDMARD treatment in the first 3 months of the pandemic; in the second stage, we investigated all patients who decided to continue treatment after interruption in the 12-month period. Results: A total of 521 patients were included in the study. The iRMD diagnosis was listed as spondyloarthritis (SpA) (54.3%), rheumatoid arthritis (RA) (25.7%), psoriatic arthritis (PsA) (8.4%), vasculitis (6.1%), and others (5.4%). Concurrent use of hydroxychloroquine (hazard ratio [HR] = 1.49), iv bDMARD use (HR = 1.34), and a history of discontinuation of drug in the first 3 months of the pandemic (HR = 1.19) were determined as factors that reduced 12-month drug retention rates. The use of glucocorticoid (HR = 3.81) and having a diagnosis of interstitial lung disease/chronic obstructive lung disease (HR = 4.96) were found to increase the risk of being infected by SARS coronavirus 2 (SARS-CoV-2). Conclusions: It was shown that approximately 1/5 of iRMD patients using b/tsDMARDs delayed their treatment due to the fear of COVID-19 in the first three months of the pandemic process. However, with good communication with the patients, b/tsDMARD treatment was restarted and the 12-month drug retention status was quite high.

show abstract

Section: Patientsmentioning

confidence: 99%